SARS-CoV-2 Spike Protein and Neutralizing Anti-Spike Protein Antibodies Modulate Blood Platelet Function

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5312 - 5312

Published: March 10, 2023

Several studies report elevated blood platelet activation and altered count in COVID-19 patients, but the role of SARS-CoV-2 spike protein this process remains intriguing. Additionally, there is no data that anti-SARS-CoV-2 neutralizing antibodies (nAb) may attenuate activity toward platelets. Our results indicate under vitro conditions, increased collagen-stimulated aggregation isolated platelets induced binding vWF to ristocetin-treated blood. The also significantly reduced collagen- or ADP-induced decreased GPIIbIIIa (fibrinogen receptor) whole blood, depending on presence anti-spike nAb. findings suggest activation/reactivity patients donors vaccinated with and/or previously-infected should be supported by measurements IgG antibody concentrations

Language: Английский

---

The lack of anti‐PF4 antibodies in convalescent plasma from COVID‐19 infected blood donor

Transfusion Medicine, Journal Year: 2023, Volume and Issue: 33(3), P. 272 - 273

Published: March 30, 2023

Language: Английский

---

Development of a Machine Learning-Based Model for the Prediction of Long-Term Erectile Dysfunction after COVID-19 Recovery: A Prospective Observational Study

Published: July 22, 2024

Objectives: To develop a machine learning-based model for the identification of features involved in prediction long-term erectile dysfunction (ED) after COVID-19 recovery. Methods: We performed an observational prospective multicentre study. Participants were divided into 2 groups: I) Patients with past history COVID-19; II) without previous microbiological diagnosis COVID-19. A total 361 patients (COVID-19 group, n=166, Control group; n=195) assessed from January 2022 to March 2023. group 12 months recovery; within same time window. The primary outcome measure was ED. including three algorithms (random forest, logistic regression and support vector machines [SVM]) applied perform automatic selection those algorithm SVM-recursive feature elimination (RFE) also executed. Results: median age 55 years both groups. final variables our was: SARS-CoV-2 vaccination status, hypertension, diabetes, beta blocker treatment, antiplatelet therapy coffee intake. SVM-RFE showed that ED predictors model. Conclusions: developed following application predictive tool community setting could avoid adverse effects unfavourable economic impact associated.

Language: Английский

---

Brazilian Medicinal Plants and Their Metabolites as Potential Antivirals Against SARS-CoV-2: a Systematic Review of Experimental Findings

Revista Brasileira de Farmacognosia, Journal Year: 2024, Volume and Issue: 34(5), P. 883 - 898

Published: April 8, 2024

Language: Английский

---

Safety Assessment of Co-Administered SARS-CoV-2 Vaccines in BALB/c Mice

International Journal of Innovative Science and Research Technology (IJISRT), Journal Year: 2024, Volume and Issue: unknown, P. 2585 - 2591

Published: June 11, 2024

The onset of Coronavirus disease 2019 (COVID-19) in late presented a severe worldwide health crisis with widespread morbidity and mortality. Various vaccine platforms have been rapidly developed approved for broad use swift urgent response to prevent the transmission Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection. However, these vaccines differ significantly terms safety. Heterologous prime-boost vaccination enhances safety compared homologous vaccination, although it could lead higher cumulative number transient adverse events reported at each visit. Therefore, additional strategies are necessary improve SARS- CoV-2 Anecdotal options suggest that co-administration can reduce effects consequently, avert need frequent booster doses. This study reports immunization outcomes against SARS-CoV-2 virus by assessing profiles different co-administered BALB/c mice. Vaccine combinations comprising mRNA/adenovirus26-vector, mRNA/inactivated, adenovirus26-vector/inactivated, mRNA/adenovirus26-vector/inactivated were prepared optimized doses, their activities upon evaluated comparison individual mRNA, adenovirus26-vectored inactivated vaccines. Twenty-eight days post-immunization, various treatments through hematological biochemical examination. Importantly, regimens proved safe well-tolerated mice, as evidenced normal values.

Language: Английский

---